UDCA ( DrugBank: UDCA )

6 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
46	悪性関節リウマチ	1
67	多発性嚢胞腎	1
93	原発性胆汁性胆管炎	83
94	原発性硬化性胆管炎	6
97	潰瘍性大腸炎	2
296	胆道閉鎖症	1

46. 悪性関節リウマチ

臨床試験数 : 4,356 / 薬物数 : 2,567 - (DrugBank : 415) / 標的遺伝子数 : 192 - 標的パスウェイ数 : 228

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04834557 (ClinicalTrials.gov)	November 1, 2021	2/4/2021	Evaluating the Effect of Digoxin and Ursodeoxycholic Acid in Patients With Rheumatoid Arthritis	Evaluating the Effect of Digoxin and Ursodeoxycholic Acid in Patients With Rheumatoid Arthritis in E ...	Rheumatoid Arthritis	Drug: Placebo;Drug: Digoxin 0.25 mg;Drug: Ursodeoxycholic acid (UDCA) 500 mg	Tanta University	NULL	Recruiting	18 Years	80 Years	All	90	Phase 2	Egypt

First Previous1Next Last

67. 多発性嚢胞腎

臨床試験数 : 221 / 薬物数 : 212 - (DrugBank : 55) / 標的遺伝子数 : 40 - 標的パスウェイ数 : 151

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-UMIN000012865	2014/06/30	01/03/2014	Ursodeoxycholic acid for polycystic liver disease	Ursodeoxycholic acid for polycystic liver disease - UDCA for PLD	polycystic liver disease, polycystic kidney disease	UDCA 600mg/day standard treatment	Nephrology Center, Toranomon Hospital	NULL	Complete: follow-up complete	Not applicable	Not applicable	Male and Female	100	Not selected	Japan

First Previous1Next Last

93. 原発性胆汁性胆管炎

臨床試験数 : 298 / 薬物数 : 252 - (DrugBank : 59) / 標的遺伝子数 : 35 - 標的パスウェイ数 : 115

diseases per page:

Showing 1 to 10 of 83 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05749822 (ClinicalTrials.gov)	February 17, 2023	29/12/2022	Fenofibrate for Compensated Cirrhosis Patients With Primary Biliary Cholangitis	Fenofibrate Combined With Ursodeoxycholic Acid in Compensated Cirrhosis Patients With Primary Biliar ...	Primary Biliary Cholangitis	Drug: Fenofibrate 200mg;Drug: Placebo;Drug: UDCA	Xijing Hospital of Digestive Diseases	NULL	Recruiting	18 Years	75 Years	All	104	Phase 2/Phase 3	China
2	NCT05293938 (ClinicalTrials.gov)	March 28, 2022	4/3/2022	A Real-World Data Study to Evaluate the Effectiveness of OCA on Hepatic Outcomes in PBC Patients	Study Evaluating the Effectiveness of Obeticholic Acid on Hepatic Real-World Outcomes in Patients Wi ...	Primary Biliary Cholangitis	Drug: Obeticholic Acid 5 MG;Drug: Obeticholic Acid 10 MG;Drug: Standard of Care: UDCA	Intercept Pharmaceuticals	Global PBC Study Group;Target RWE;Syneos Health;UK PBC Study Group	Enrolling by invitation	18 Years	N/A	All	2350		United States
3	EUCTR2020-004348-27-DK (EUCTR)	04/03/2022	22/11/2021	A clinical trial to assess the safety and efficacy of seladelpar in patientswith primary biliary cho ...	RESPONSE: A Placebo-controlled, Randomized, Phase 3 Study to Evaluate the Efficacy and Safety of Sel ...	Primary biliary cholangitis (PBC, formerly known as primary biliarycirrhosis) is a serious and poten ...	Product Name: Seladelpar Product Code: MBX-8025 INN or Proposed INN: SELADELPAR Product Name: Seladelpa ...	CymaBay Therapeutics, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	180	Phase 3	Mexico;Canada;Argentina;Poland;Belgium;Romania;Germany;New Zealand;United States;Greece;Spain;Ukrain ...
4	NCT05104853 (ClinicalTrials.gov)	January 25, 2022	22/10/2021	Study to Evaluate the Safety, Tolerability, PDs, and Efficacy of CNP-104 in Subjects With Primary Bi ...	A Phase 2a Double Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability, Pharmacodyna ...	Primary Biliary Cholangitis	Drug: CNP-104;Drug: Placebo	COUR Pharmaceutical Development Company, Inc.	NULL	Recruiting	18 Years	75 Years	All	40	Phase 1/Phase 2	United States
5	NCT04956328 (ClinicalTrials.gov)	July 22, 2021	1/7/2021	Study of Obeticholic Acid(OCA) Combination With Ursodeoxycholic Acid (UDCA) in Patients With Primay ...	A Multi-center, Randomized, Double-blind Trail Evaluating the Efficacy and Safety of Combination of ...	Primary Biliary Cirrhosis	Drug: Obeticholic Acid Tablets;Drug: UDCA;Drug: Placebo	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	NULL	Recruiting	18 Years	75 Years	All	120	Phase 3	China
6	EUCTR2020-004348-27-RO (EUCTR)	08/07/2021	19/04/2022	A clinical trial to assess the safety and efficacy of seladelpar in patientswith primary biliary cho ...	RESPONSE: A Placebo-controlled, Randomized, Phase 3 Study to Evaluate the Efficacy and Safety of Sel ...	Primary biliary cholangitis (PBC, formerly known as primary biliarycirrhosis) is a serious and poten ...	Product Name: Seladelpar Product Code: MBX-8025 INN or Proposed INN: SELADELPAR Product Name: Seladelpa ...	CymaBay Therapeutics, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	180	Phase 3	United States;Greece;Spain;Chile;Israel;Russian Federation;United Kingdom;Italy;France;Hungary;Mexic ...
7	EUCTR2020-004348-27-DE (EUCTR)	07/07/2021	07/01/2021	A clinical trial to assess the safety and efficacy of seladelpar in patientswith primary biliary cho ...	RESPONSE: A Placebo-controlled, Randomized, Phase 3 Study to Evaluate the Efficacy and Safety of Sel ...	Primary biliary cholangitis (PBC, formerly known as primary biliarycirrhosis) is a serious and poten ...	Product Name: Seladelpar Product Code: MBX-8025 INN or Proposed INN: SELADELPAR Product Name: Seladelpa ...	CymaBay Therapeutics, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	180	Phase 3	United States;Greece;Spain;Ukraine;Russian Federation;Israel;Chile;Italy;France;Australia;Denmark;Ne ...
8	EUCTR2020-004348-27-NL (EUCTR)	08/06/2021	16/03/2021	A clinical trial to assess the safety and efficacy of seladelpar in patientswith primary biliary cho ...	RESPONSE: A Placebo-controlled, Randomized, Phase 3 Study to Evaluate the Efficacy and Safety of Sel ...	Primary biliary cholangitis (PBC, formerly known as primary biliarycirrhosis) is a serious and poten ...	Product Name: Seladelpar Product Code: MBX-8025 INN or Proposed INN: SELADELPAR Product Name: Seladelpa ...	CymaBay Therapeutics, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	180	Phase 3	United States;Greece;Spain;Ukraine;Israel;Chile;Russian Federation;Italy;France;Australia;Denmark;Ne ...
9	ChiCTR2100046346	2021-06-01	2021-05-14	A single-center, randomized, single-blind clinical study to evaluate the efficacy and safety of rifa ...	A single-center, randomized, single-blind clinical study to evaluate the efficacy and safety of rifa ...	primary biliary cholangitis	Ursodeoxycholic acid group:Ursodeoxycholic acid;Rifaximin group :UDCA and rifaximin;	Xiangya Hospital of Central South University	NULL	Recruiting	18	75	Both	Ursodeoxycholic acid group:30;Rifaximin group :30;	N/A	China
10	NCT04620733 (ClinicalTrials.gov)	April 21, 2021	4/11/2020	RESPONSE: Response to Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequat ...	RESPONSE: A Placebo-controlled, Randomized, Phase 3 Study to Evaluate the Efficacy and Safety of Sel ...	Primary Biliary Cholangitis	Drug: Seladelpar 10 mg;Drug: Placebo;Drug: Seladelpar 5 mg	CymaBay Therapeutics, Inc.	NULL	Active, not recruiting	18 Years	75 Years	All	193	Phase 3	United States;Argentina;Australia;Austria;Belgium;Canada;Chile;Czechia;Denmark;France;Germany;Greece ...

First Previous1 2 3 4 5…9Next Last

先頭へ

94. 原発性硬化性胆管炎

臨床試験数 : 148 / 薬物数 : 118 - (DrugBank : 39) / 標的遺伝子数 : 18 - 標的パスウェイ数 : 141

diseases per page:

Showing 1 to 6 of 6 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04309773 (ClinicalTrials.gov)	April 6, 2021	18/10/2019	Efficacy of 24 Month of Bezafibrate in Primary Sclerosing Cholangitis With Persistent Cholestasis De ...	Double Blind, Multicentric, Randomized, Placebo-controlled Trial, Evaluating the Efficacy of 24 Mont ...	Primary Sclerosing Cholangitis;Cholestasis	Drug: Bezafibrate (400mg) in addition to standard 15-20 mg/kg/jour UDCAtherapy;Drug: Placebo of Beza ...	Assistance Publique - Hôpitaux de Paris	NULL	Recruiting	18 Years	75 Years	All	104	Phase 3	France
2	NCT03678480 (ClinicalTrials.gov)	March 1, 2021	18/9/2018	A Study of HTD1801 in Adolescents With Primary Sclerosing Cholangitis (PSC)	A Phase 2, Randomized, Double-Blind Study of HTD1801 vs Ursodeoxycholic Acid (UDCA) in Adolescents W ...	Primary Sclerosing Cholangitis;Cholangitis;Cholangitis, Sclerosing;Bile Duct Diseases;Biliary Tract ...	Drug: HTD1801;Drug: Ursodeoxycholic Acid	HighTide Biopharma Pty Ltd	NULL	Withdrawn	12 Years	17 Years	All	0	Phase 2	NULL
3	NCT03516006 (ClinicalTrials.gov)	January 2017	20/9/2017	Umbilical Cord Mesenchymal Stem Cells in Primary Sclerosing Cholangitis	Intra-arterial Injection of Umbilical Cord Mesenchymal Stem Cells in Primary Sclerosing Cholangitis	Primary Sclerosing Cholangitis	Drug: UCMSC;Drug: UDCA	Fuzhou General Hospital	NULL	Active, not recruiting	18 Years	65 Years	All	20	Phase 1/Phase 2	NULL
4	EUCTR2015-003310-24-SE (EUCTR)	09/10/2015	01/09/2015	Ursodeoxycholic Acid (UDCA) in Preventing Hepatobiliary and Colorectal Malignancy in Surveillance Pa ...	A Phase 3, Open-label, Randomized, Prospective Clinical Trial Evaluating the Efficacy of Stratified ...	Primary sclerosing cholangitis with or without concomitant inflammatory bowel disease included in an ...	Trade Name: Ursofalk Product Name: Ursofalk	Sahlgrenska Academy	NULL	Not Recruiting			Female: yes Male: yes	500	Phase 3	Sweden
5	NCT01456468 (ClinicalTrials.gov)	October 2011	14/10/2011	Combination Therapy With Ursodeoxycholic Acid (UDCA) and All-Trans Retinoic Acid (ATRA) for Treatmen ...	Combination Therapy With Ursodeoxycholic Acid (UDCA) and All-Trans Retinoic Acid (ATRA) for Treatmen ...	Cholangitis, Sclerosing	Drug: Oral all-trans retinoic acid (ATRA)	Yale University	Mayo Clinic	Completed	18 Years	80 Years	Both	19	Phase 1	United States
6	NCT01088607 (ClinicalTrials.gov)	October 2010	12/3/2010	Safety and Efficacy Study of Ursodeoxycholic Acid Therapy in Pediatric Primary Sclerosing Cholangiti ...	Ursodeoxycholic Acid Therapy in Pediatric Primary Sclerosing Cholangitis: A Pilot Withdrawal/Reinsti ...	Primary Sclerosing Cholangitis	Drug: ursodeoxycholic acid (UDCA)	University of Tennessee	Icahn School of Medicine at Mount Sinai;Ann & Robert H Lurie Children's Hospital of Chicago;Universi ...	Completed	5 Years	21 Years	All	27	Phase 1	United States;Canada

First Previous1Next Last

先頭へ

97. 潰瘍性大腸炎

臨床試験数 : 2,630 / 薬物数 : 1,459 - (DrugBank : 265) / 標的遺伝子数 : 144 - 標的パスウェイ数 : 202

diseases per page:

Showing 1 to 2 of 2 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03724175 (ClinicalTrials.gov)	August 26, 2019	12/10/2018	The Role of Secondary Bile Acids in Intestinal Inflammation	The Role of Secondary Bile Acids in Intestinal Inflammation	Ulcerative Colitis;Pouchitis	Drug: ursodiol (ursodeoxycholic acid, UDCA)	Stanford University	NULL	Recruiting	18 Years	70 Years	All	15	Phase 2/Phase 3	United States
2	EUCTR2009-010921-38-NL (EUCTR)	08/09/2009	02/03/2009	Chemopreventive effects of 5-ASA and UDCAin Ulcerative Colitis:A Double-blind, Randomized Placebo-co ...	Chemopreventive effects of 5-ASA and UDCAin Ulcerative Colitis:A Double-blind, Randomized Placebo-co ...	Ulcerative Colitis and the risk of developing colorectal cancer. MedDRA version: 13.1;Level: PT;Clas ...	Trade Name: Salofalk INN or Proposed INN: mesalazine Trade Name: Ursofalk INN or Proposed INN: ursodeox ...	UMC Utrecht	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes			Netherlands

First Previous1Next Last

296. 胆道閉鎖症

臨床試験数 : 71 / 薬物数 : 70 - (DrugBank : 39) / 標的遺伝子数 : 35 - 標的パスウェイ数 : 60

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	ChiCTR1800015250	2018-01-01	2018-03-19	The Effect of Adjuvant UDCATherapy Post-Kasai Portoenterostomy in Biliary Atresia: a multicenter ran ...	The Effect of Adjuvant UDCATherapy Post-Kasai Portoenterostomy in Biliary Atresia: a multicenter ran ...	biliary atresia	high-dose:UDCA 25mg/kg po;low-dose:UDCA 15mg/kg po;	Children's Hospital of Fudan University	NULL	Recruiting			Both	high-dose:100;low-dose:100;		China

First Previous1Next Last

先頭へ